Immunic Inc. Stock
Immunic Inc. Stock
Heavy losses for Immunic Inc. today as the stock fell by -€0.138 (-11.640%).
With 25 Buy predictions and not a single Sell prediction Immunic Inc. is an absolute favorite of our community.
With a target price of 8 € there is potential for a 676.7% increase which would mean more than doubling the current price of 1.03 € for Immunic Inc..
So far the community has only identified positive things for Immunic Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Immunic Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | -11.640% | -4.097% | 33.247% | 0.195% | 139.535% | -33.225% | -92.426% |
| NanoViricides Inc. | 0.520% | 20.625% | 19.136% | -11.468% | 3.763% | -15.831% | -77.558% |
| Ocuphire Pharma Inc. | 1.420% | 4.502% | 43.883% | 404.577% | 162.188% | 33.839% | - |
| Actinium Pharmaceuticals Inc. | -0.400% | -3.526% | 4.399% | -11.341% | -18.393% | -88.189% | -87.124% |
Comments
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $8.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
News
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update